PL3201203T3 - Krystaliczna postać 1-(1-metylo-1h-pirazol-4-ilo)-n-((1r,5s,7s)-9-metylo-3-oksa-9-azabicyklo[3.3.1]nonan-7-ylo)-1h-indolo-3-karboksyamidu - Google Patents

Krystaliczna postać 1-(1-metylo-1h-pirazol-4-ilo)-n-((1r,5s,7s)-9-metylo-3-oksa-9-azabicyklo[3.3.1]nonan-7-ylo)-1h-indolo-3-karboksyamidu

Info

Publication number
PL3201203T3
PL3201203T3 PL15778162T PL15778162T PL3201203T3 PL 3201203 T3 PL3201203 T3 PL 3201203T3 PL 15778162 T PL15778162 T PL 15778162T PL 15778162 T PL15778162 T PL 15778162T PL 3201203 T3 PL3201203 T3 PL 3201203T3
Authority
PL
Poland
Prior art keywords
methyl
nonan
azabicyclo
pyrazol
oxa
Prior art date
Application number
PL15778162T
Other languages
English (en)
Polish (pl)
Inventor
Yuxin Zhao
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of PL3201203T3 publication Critical patent/PL3201203T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15778162T 2014-09-29 2015-09-29 Krystaliczna postać 1-(1-metylo-1h-pirazol-4-ilo)-n-((1r,5s,7s)-9-metylo-3-oksa-9-azabicyklo[3.3.1]nonan-7-ylo)-1h-indolo-3-karboksyamidu PL3201203T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462056982P 2014-09-29 2014-09-29
PCT/US2015/052806 WO2016053947A1 (en) 2014-09-29 2015-09-29 Crystalline form of 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide
EP15778162.6A EP3201203B1 (en) 2014-09-29 2015-09-29 Crystalline form of 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide

Publications (1)

Publication Number Publication Date
PL3201203T3 true PL3201203T3 (pl) 2021-11-22

Family

ID=54289137

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15778162T PL3201203T3 (pl) 2014-09-29 2015-09-29 Krystaliczna postać 1-(1-metylo-1h-pirazol-4-ilo)-n-((1r,5s,7s)-9-metylo-3-oksa-9-azabicyklo[3.3.1]nonan-7-ylo)-1h-indolo-3-karboksyamidu

Country Status (12)

Country Link
US (1) US10329306B2 (enExample)
EP (1) EP3201203B1 (enExample)
JP (2) JP7055017B2 (enExample)
CN (1) CN106795172B (enExample)
CA (1) CA2962429C (enExample)
DK (1) DK3201203T3 (enExample)
ES (1) ES2883295T3 (enExample)
HU (1) HUE055175T2 (enExample)
MA (1) MA40771B1 (enExample)
PL (1) PL3201203T3 (enExample)
PT (1) PT3201203T (enExample)
WO (1) WO2016053947A1 (enExample)

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
FI74707C (fi) 1982-06-29 1988-03-10 Sandoz Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara alkylenoeverbryggade piperidylestrar eller -amider av bicykliska karboxylsyror.
JPS5936675A (ja) 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
GB8510752D0 (en) 1985-04-27 1985-06-05 Beecham Group Plc Compounds
DE3650772T2 (de) 1985-04-27 2003-04-03 F. Hoffmann-La Roche Ag, Basel Derivate von Indazole-3-carboxamide und -3-carboxylsäure
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE3722069A1 (de) 1986-08-21 1988-02-25 Toyoda Gosei Kk Signalhornschaltvorrichtung fuer ein steuerrad
DE3777805D1 (de) 1986-11-21 1992-04-30 Glaxo Group Ltd Arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
IT1226389B (it) 1988-07-12 1991-01-15 Angeli Inst Spa Nuovi derivati ammidinici e guanidinici
GB8829079D0 (en) 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
JPH0421681A (ja) 1990-05-14 1992-01-24 Fujisawa Pharmaceut Co Ltd ピロロピリジン誘導体
JP3251954B2 (ja) 1990-07-31 2002-01-28 日清ファルマ株式会社 アザビシクロ誘導体
US5187166A (en) 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
HU211081B (en) 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5149962A (en) 1991-06-03 1992-09-22 Simmonds Precision Products, Inc. Proximity detector using faraday effect and bidirectional transmission
US5344831A (en) 1992-01-31 1994-09-06 Nisshin Flour Milling Co., Ltd. Diazabicyclo derivatives
GB9216154D0 (en) 1992-07-30 1992-09-09 Glaxo Group Ltd Chemical compounds
GB9406857D0 (en) 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
JP3904254B2 (ja) 1994-10-20 2007-04-11 株式会社日清製粉グループ本社 ５−ｈｔ４受容体作動薬
CA2160420A1 (en) 1994-10-20 1996-04-21 Haruhiko Kikuchi 5-ht4 receptor agonists
WO1996012722A1 (en) 1994-10-20 1996-05-02 Nisshin Flour Milling Co., Ltd. 5-ht4 receptor agonist
WO2000044743A1 (en) 1999-01-28 2000-08-03 Nippon Shinyaku Co., Ltd. Amide derivatives and drug compositions
AU1887401A (en) 1999-12-14 2001-06-25 Nippon Shinyaku Co. Ltd. Medicinal composition
EP1427707A1 (en) 2001-09-19 2004-06-16 Pharmacia Corporation Substituted indazole compounds for the treatment of inflammation
US20040038958A1 (en) 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
ES2405594T3 (es) 2002-09-25 2013-05-31 Memory Pharmaceuticals Corporation Idazoles, benzotiazoles y benzisotiazoles, y preparación y usos de los mismos
NZ541008A (en) 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating functional bowel disorders
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
BRPI0508771A (pt) 2004-03-25 2007-08-14 Memory Pharm Corp indazóis, benzotiazóis, benzoisotiazóis, benzisoxazóis, e a preparação e usos dos mesmos
UA93348C2 (ru) 2004-03-25 2011-02-10 Меморі Фармас'Ютікалз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, их получение и применение
JP2008527028A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類
KR20080048550A (ko) 2005-09-23 2008-06-02 메모리 파마슈티칼스 코포레이션 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸,피라졸로피리딘, 이소티아졸로피리딘, 및 이들의 제법 및용도
EP1984334B1 (en) 2006-02-15 2014-04-09 Allergan, Inc. Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
CN101460458A (zh) 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
KR101288781B1 (ko) 2006-06-28 2013-07-22 암젠 인크 글리신 수송자-1 억제제
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2008097930A1 (en) 2007-02-05 2008-08-14 Amira Pharmaceuticals, Inc. Reverse indoles as 5-lipoxygenase-activating protein (flap) inhibitors
MX2009008439A (es) 2007-02-12 2009-08-13 Intermune Inc Nuevos inhibidores de la replicacion del virus de hepatitis c.
BRPI0812594A2 (pt) 2007-08-10 2015-06-23 Lundbeck & Co As H Composto ou sal ou hidrato do mesmo, composição farmacêutica, métodos para modulação da atividade de um receptor p2x7, para tratamento de uma condição responsiva á modulação do receptor p2x7 em um paciente, para inibição de morte de células gangliônicas retinais em um paciente, para determinação da presença ou ausência de receptor p2x7 em uma amostra, preparação farmacêutica acondicionada, e, uso de um composto ou sal ou hidrato do mesmo.
WO2009108551A2 (en) 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
EP2310019A4 (en) 2008-05-29 2011-06-01 Albany Molecular Res Inc 5-HT3 RECEPTOR MODULATORS, MANUFACTURING METHOD AND ITS USE
TWI429628B (zh) 2010-03-29 2014-03-11 Univ Taipei Medical 吲哚基或吲哚啉基羥肟酸化合物
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5

Also Published As

Publication number Publication date
MA40771B1 (fr) 2021-09-30
JP7055017B2 (ja) 2022-04-15
CN106795172A (zh) 2017-05-31
CN106795172B (zh) 2020-07-28
US10329306B2 (en) 2019-06-25
HUE055175T2 (hu) 2021-11-29
DK3201203T3 (da) 2021-08-23
ES2883295T3 (es) 2021-12-07
JP2017529379A (ja) 2017-10-05
JP2022036978A (ja) 2022-03-08
EP3201203A1 (en) 2017-08-09
WO2016053947A1 (en) 2016-04-07
CA2962429C (en) 2023-01-03
CA2962429A1 (en) 2016-04-07
EP3201203B1 (en) 2021-05-19
PT3201203T (pt) 2021-08-09
US20170233406A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
CA3286859A1 (en) Use of 3-isoxazolidinones compounds as selective herbicides
EP3204433B8 (en) Process for the preparation of an alpha-nucleated polypropylene
EP3137141A4 (en) Vaporizer
EP3191449A4 (en) Novel compounds as rearranged during transfection (ret) inhibitors
IL247901A0 (en) Additional salts of (s)-2-(1-(6-amino-5-cyanopyrimidine-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1 ,2,4]triazine-5-carbonitrile
EP3142597A4 (en) Spatially improved extented reach ultrasonic toothbrush
EP3209653A4 (en) Process for the preparation of (r,s)-nicotine
EP3142608A4 (en) Replacement heart valve
EP3149549A4 (en) Active container
EP3177285A4 (en) [5,6]-fused bicyclic antidiabetic compounds
EP3136857A4 (en) Crystalline form of baricitinib
EP3125982A4 (en) Headgear for respiratory interfaces
EP3119401A4 (en) Cenicriviroc for the treatment of fibrosis
EP3143153A4 (en) Microbial approach for the production of 5-hydroxytryptophan
EP3124850A4 (en) Cradle head
EP3177614A4 (en) [7,6]-fused bicyclic antidiabetic compounds
EP3116498A4 (en) Formulation for soft anticholinergic analogs
EP3174393A4 (en) Dual biocide generator
EP3205458A4 (en) Adsorption nozzle
IL248267A0 (en) A process for preparing converted cycloserines
EP3113773A4 (en) Crystalline forms of grapiprant
EP3094316A4 (en) Fullerene compounds as antioxidant therapy
EP3125876B8 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
EP3140308B8 (en) Process for the preparation of opioid compounds
EP3221320A4 (en) A process for the preparation of ibrutinib